Healthcare provider profile · identity verified

Luma Ibrahim

Internal Medicine · PHOENIX, AZ · NPI 1619323763

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	250	96
Atorvastatin Calcium	Atorvastatin Calcium	241	108
Rosuvastatin Calcium	Rosuvastatin Calcium	196	83
Levothyroxine Sodium	Levothyroxine Sodium	177	72
Amlodipine Besylate	Amlodipine Besylate	171	69
Lisinopril	Lisinopril	154	75
Omeprazole	Omeprazole	143	62
Albuterol Sulfate Hfa	Albuterol Sulfate	116	78
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	98	41
Gabapentin	Gabapentin	95	37
Metoprolol Tartrate	Metoprolol Tartrate	84	35
Metformin Hcl	Metformin Hcl	83	37
Glipizide	Glipizide	78	28
Metformin Hcl Er	Metformin Hcl	76	34
Atenolol	Atenolol	73	33
Hydrochlorothiazide	Hydrochlorothiazide	72	25
Ibuprofen	Ibuprofen	64	38
Simvastatin	Simvastatin	63	26
Meloxicam	Meloxicam	57	37
Potassium Chloride	Potassium Chloride	56	29
Trazodone Hcl	Trazodone Hcl	56	28
Triamcinolone Acetonide	Triamcinolone Acetonide	50	28
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	49	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	46	19
Jardiance	Empagliflozin	44	18
Doxycycline Monohydrate	Doxycycline Monohydrate	42	37
Ozempic	Semaglutide	42	suppressed
Donepezil Hcl	Donepezil Hcl	41	suppressed
Finasteride	Finasteride	40	suppressed
Furosemide	Furosemide	39	20
Cefadroxil	Cefadroxil	37	33
Fluoxetine Hcl	Fluoxetine Hcl	36	14
Terazosin Hcl	Terazosin Hcl	36	13
Ezetimibe	Ezetimibe	35	16
Alendronate Sodium	Alendronate Sodium	30	18
Allopurinol	Allopurinol	30	15
Tamsulosin Hcl	Tamsulosin Hcl	29	12
Estradiol	Estradiol	26	11
Metoprolol Succinate	Metoprolol Succinate	26	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	25	25
Ondansetron Odt	Ondansetron	25	14
Oxybutynin Chloride Er	Oxybutynin Chloride	25	suppressed
Sertraline Hcl	Sertraline Hcl	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Prednisone	Prednisone	21	18
Fluticasone Propionate	Fluticasone Propionate	20	suppressed
Mirtazapine	Mirtazapine	20	11
Azithromycin	Azithromycin	19	18
Lovastatin	Lovastatin	19	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	19	13
Bupropion Xl	Bupropion Hcl	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	18	suppressed
Eliquis	Apixaban	18	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	17	17
Alvesco	Ciclesonide	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	17	14
Bisoprolol Fumarate	Bisoprolol Fumarate	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Metronidazole	Metronidazole	15	11
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Breyna	Budesonide/Formoterol Fumarate	14	11
Fenofibrate	Fenofibrate	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	13	13
Carvedilol	Carvedilol	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	13
Tizanidine Hcl	Tizanidine Hcl	13	11
Acyclovir	Acyclovir	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error